<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Diabetes Mellitus TLM - Teaching Learning Material</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            line-height: 1.6;
            color: #333;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            min-height: 100vh;
        }

        .presentation {
            max-width: 1200px;
            margin: 0 auto;
            background: white;
            box-shadow: 0 10px 30px rgba(0,0,0,0.3);
        }

        .slide {
            min-height: 100vh;
            padding: 60px;
            display: none;
            position: relative;
        }

        .slide.active {
            display: block;
        }

        .slide-title {
            font-size: 2.5rem;
            font-weight: bold;
            color: #2c3e50;
            margin-bottom: 30px;
            text-align: center;
            border-bottom: 4px solid #3498db;
            padding-bottom: 20px;
        }

        .slide-subtitle {
            font-size: 1.8rem;
            color: #7f8c8d;
            text-align: center;
            margin-bottom: 40px;
        }

        .content-section {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 40px;
            margin-top: 30px;
        }

        .content-box {
            background: #f8f9fa;
            padding: 30px;
            border-radius: 15px;
            border-left: 5px solid;
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
        }

        .type1 { border-left-color: #e74c3c; }
        .type2 { border-left-color: #f39c12; }
        .diagnosis { border-left-color: #27ae60; }
        .treatment { border-left-color: #9b59b6; }

        .definition-box {
            background: #ecf0f1;
            padding: 30px;
            border-radius: 15px;
            margin: 20px 0;
            border: 2px solid #3498db;
        }

        .criteria-table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
        }

        .criteria-table th, .criteria-table td {
            padding: 15px;
            text-align: left;
            border-bottom: 1px solid #ddd;
        }

        .criteria-table th {
            background: #3498db;
            color: white;
            font-weight: bold;
        }

        .criteria-table tr:nth-child(even) { background: #f8f9fa; }

        .pathophysiology-diagram {
            text-align: center;
            margin: 30px 0;
        }

        .flow-diagram {
            display: inline-block;
            background: white;
            padding: 30px;
            border-radius: 15px;
            box-shadow: 0 5px 15px rgba(0,0,0,0.1);
        }

        .risk-factors {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin: 30px 0;
        }

        .risk-factor {
            background: linear-gradient(45deg, #ffeaa7, #fab1a0);
            padding: 20px;
            border-radius: 10px;
            text-align: center;
        }

        .clinical-features {
            list-style: none;
        }

        .clinical-features li {
            background: #ecf0f1;
            margin: 10px 0;
            padding: 15px;
            border-radius: 8px;
            border-left: 4px solid #e74c3c;
        }

        .complications-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
        }

        .complication {
            background: #ffeaea;
            padding: 20px;
            border-radius: 10px;
            border: 2px solid #e74c3c;
        }

        .treatment-algo {
            text-align: center;
            margin: 30px 0;
        }

        .treatment-step {
            display: inline-block;
            background: #2ecc71;
            color: white;
            padding: 20px;
            border-radius: 10px;
            margin: 0 10px;
            font-weight: bold;
        }

        .prevention-strategies {
            background: linear-gradient(45deg, #74b9ff, #0984e3);
            color: white;
            padding: 30px;
            border-radius: 15px;
            margin: 30px 0;
        }

        .navigation {
            position: fixed;
            bottom: 20px;
            left: 50%;
            transform: translateX(-50%);
            background: rgba(0,0,0,0.8);
            color: white;
            padding: 15px 30px;
            border-radius: 25px;
            display: flex;
            gap: 20px;
            z-index: 1000;
        }

        .nav-btn {
            background: #3498db;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 20px;
            cursor: pointer;
            font-size: 16px;
            transition: all 0.3s;
        }

        .nav-btn:hover {
            background: #2980b9;
        }

        .nav-btn:disabled {
            background: #95a5a6;
            cursor: not-allowed;
        }

        .slide-counter {
            background: #34495e;
            color: white;
            padding: 5px 15px;
            border-radius: 15px;
            margin-left: 20px;
        }

        .highlight {
            background: #f1c40f;
            padding: 2px 5px;
            border-radius: 3px;
        }

        .case-study {
            background: #d5dbdb;
            border: 2px solid #27ae60;
            padding: 20px;
            border-radius: 10px;
            margin: 20px 0;
        }

        .key-points {
            background: #ecf0f1;
            border-left: 4px solid #f39c12;
            padding: 15px;
            margin: 15px 0;
        }

        .learning-objectives {
            background: #f8f9fa;
            border: 2px solid #9b59b6;
            padding: 20px;
            border-radius: 10px;
            margin: 20px 0;
        }

        @media (max-width: 768px) {
            .slide {
                padding: 30px 20px;
            }

            .content-section {
                grid-template-columns: 1fr;
            }

            .slide-title {
                font-size: 2rem;
            }

            .navigation {
                padding: 10px 20px;
            }

            .nav-btn {
                padding: 8px 15px;
                font-size: 14px;
            }
        }
    </style>
</head>
<body>
    <div class="presentation">
        <!-- Title Slide -->
        <div class="slide active" id="slide0">
            <h1 class="slide-title">Diabetes Mellitus</h1>
            <h2 class="slide-subtitle">Teaching Learning Material for MBBS Students</h2>

            <div class="content-section">
                <div class="content-box type1">
                    <h3>Objectives</h3>
                    <ul>
                        <li>Understand pathophysiology & classification</li>
                        <li>Master diagnostic criteria & screening</li>
                        <li>Apply evidence-based treatment</li>
                        <li>Implement prevention strategies</li>
                        <li>Focus on Indian epidemiological context</li>
                    </ul>
                </div>

                <div class="content-box type2">
                    <h3>Topics Covered</h3>
                    <ul>
                        <li>Definition & Criteria</li>
                        <li>Epidemiology & Burden</li>
                        <li>Pathophysiology</li>
                        <li>Types of Diabetes</li>
                        <li>Risk Factors & Etiology</li>
                        <li>Clinical Features</li>
                        <li>Diagnosis & Management</li>
                        <li>Prevention Strategies</li>
                    </ul>
                </div>
            </div>

            <div class="learning-objectives">
                <h4>Learning Objectives</h4>
                <p>‚Ä¢ Master diabetes pathophysiology across different types</p>
                <p>‚Ä¢ Apply ADA diagnostic guidelines confidently</p>
                <p>‚Ä¢ Develop comprehensive management plans</p>
                <p>‚Ä¢ Understand India-specific epidemiological patterns</p>
                <p>‚Ä¢ Implement lifestyle and pharmacological interventions</p>
            </div>
        </div>

        <!-- Definition & Criteria -->
        <div class="slide" id="slide1">
            <h1 class="slide-title">Definition & Diagnostic Criteria</h1>

            <div class="definition-box">
                <strong>Diabetes Mellitus (DM)</strong> is a group of metabolic disorders characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both.
            </div>

            <div class="content-section">
                <div class="content-box diagnosis">
                    <h3>ADA Diagnostic Criteria (2024)</h3>
                    <table class="criteria-table">
                        <thead>
                            <tr>
                                <th>Parameter</th>
                                <th>Diabetes</th>
                                <th>Prediabetes</th>
                                <th>Normal</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>Fasting Plasma Glucose</strong></td>
                                <td>‚â•126 mg/dL</td>
                                <td>100-125 mg/dL</td>
                                <td><100 mg/dL</td>
                            </tr>
                            <tr>
                                <td><strong>2h PG (OGTT)</strong></td>
                                <td>‚â•200 mg/dL</td>
                                <td>140-199 mg/dL</td>
                                <td><140 mg/dL</td>
                            </tr>
                            <tr>
                                <td><strong>HbA1c</strong></td>
                                <td>‚â•6.5%</td>
                                <td>5.7-6.4%</td>
                                <td><5.7%</td>
                            </tr>
                            <tr>
                                <td><strong>Random PG</strong></td>
                                <td>‚â•200 mg/dL + symptoms</td>
                                <td>-</td>
                                <td><200 mg/dL</td>
                            </tr>
                        </tbody>
                    </table>

                    <div class="key-points">
                        <strong>Key Points:</strong><br>
                        ‚Ä¢ Symptomatic patients: Any single abnormal value diagnostic<br>
                        ‚Ä¢ Asymptomatic: Require repeat testing unless HbA1c ‚â•6.5%<br>
                        ‚Ä¢ Always use plasma glucose, not whole blood<br>
                        ‚Ä¢ Confirmatory OGTT gold standard in specific situations
                    </div>
                </div>

                <div class="content-box type1">
                    <h3>WHO Definition</h3>
                    <p>A metabolic disorder characterized by chronic hyperglycemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.</p>

                    <h4>Historical Perspective</h4>
                    <ul>
                        <li><strong>Ancient times</strong>: Known as "Honey Urine"</li>
                        <li><strong>1921</strong>: Insulin discovery (Banting & Best)</li>
                        <li><strong>1950s-1980s</strong>: Type classification</li>
                        <li><strong>1990s-2020s</strong>: New oral agents, incretins</li>
                    </ul>
                </div>
            </div>
        </div>

        <!-- Epidemiology & Burden -->
        <div class="slide" id="slide2">
            <h1 class="slide-title">Epidemiology & Disease Burden</h1>

            <div class="content-section">
                <div class="content-box type2">
                    <h3>Global Statistics (2021)</h3>
                    <ul class="clinical-features">
                        <li><strong>Prevalence</strong>: 537 million adults (10.5%)</li>
                        <li><strong>2030 Projection</strong>: 643 million</li>
                        <li><strong>2045 Projection</strong>: 783 million</li>
                        <li><strong>Annual deaths</strong>: 6.7 million</li>
                        <li><strong>Ranking</strong>: 9th leading cause globally</li>
                    </ul>

                    <h4>Regional Distribution</h4>
                    <ul>
                        <li><strong>Highest</strong>: Middle East & N Africa (14.0%)</li>
                        <li><strong>South Asia</strong>: 8.8% (second highest)</li>
                        <li><strong>North America</strong>: 11.7%</li>
                        <li><strong>Western Europe</strong>: 5.4%</li>
                    </ul>
                </div>

                <div class="content-box diagnosis">
                    <h3>Diabetes in India</h3>
                    <ul class="clinical-features">
                        <li><strong>Total cases</strong>: 101.2 million (2021)</li>
                        <li><strong>Prevalence</strong>: 11.4% (20-79 years)</li>
                        <li><strong>2030 Projection</strong>: 140.2 million</li>
                        <li><strong>2045 Projection</strong>: 160 million</li>
                        <li><strong>Annual deaths</strong>: 240,000-300,000</li>
                    </ul>

                    <div class="key-points">
                        <strong>Disease Burden:</strong><br>
                        ‚Ä¢ Economic cost: $40-50 billion annually<br>
                        ‚Ä¢ DALYs lost: 8.5 million (2.4% of total)<br>
                        ‚Ä¢ Healthcare expenditure: 10-15%</strong>
                    </div>
                </div>
            </div>

            <div class="prevention-strategies">
                <h3>State-Wise Variations (2021)</h3>
                <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(200px, 1fr)); gap: 20px; margin-top: 20px;">
                    <div><strong>Kerala</strong>: 19.2%</div>
                    <div><strong>Goa</strong>: 17.8%</div>
                    <div><strong>Tamil Nadu</strong>: 14.6%</div>
                    <div><strong>Punjab</strong>: 14.8%</div>
                    <div><strong>Delhi</strong>: 13.4%</div>
                    <div><strong>Maharashtra</strong>: 10.4%</div>
                </div>
            </div>
        </div>

        <!-- Pathophysiology -->
        <div class="slide" id="slide3">
            <h1 class="slide-title">Pathophysiology</h1>

            <div class="pathophysiology-diagram">
                <div class="flow-diagram">
                    <h3>Mechanisms of Hyperglycemia</h3>
                    <div style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 20px; margin: 30px 0;">
                        <div style="background: #ffeaa7; padding: 20px; border-radius: 10px; text-align: center;">
                            <h4>Type 1 DM</h4>
                            <p>Autoimmune Œ≤-cell destruction<br><strong>Absolute insulin deficiency</strong></p>
                        </div>
                        <div style="background: #ff7675; padding: 20px; border-radius: 10px; text-align: center;">
                            <h4>Type 2 DM</h4>
                            <p>Insulin resistance +<br>Œ≤-cell dysfunction<br><strong>Relative insulin deficiency</strong></p>
                        </div>
                        <div style="background: #a29bfe; padding: 20px; border-radius: 10px; text-align: center;">
                            <h4>Common Pathways</h4>
                            <p>Glucotoxicity<br>Lipotoxicity<br>Oxidative stress</p>
                        </div>
                    </div>
                </div>
            </div>

            <div class="content-section">
                <div class="content-box type1">
                    <h3>Type 1 Pathogenesis</h3>
                    <div class="case-study">
                        <strong>Stages:</strong><br>
                        1. Genetic predisposition (HLA-DRs)<br>
                        2. Environmental triggers (viral, toxins)<br>
                        3. Autoimmune activation (ICA, GAD)<br>
                        4. Œ≤-cell destruction ‚Üí Absolute deficiency
                    </div>

                    <h4>Autoimmune Markers</h4>
                    <ul>
                        <li><strong>GAD antibodies</strong>: 70-80%</li>
                        <li><strong>IA-2 antibodies</strong>: 50-60%</li>
                        <li><strong>ICA</strong>: 70-90% at diagnosis</li>
                        <li><strong>C-peptide</strong>: Low/undetectable</li>
                    </ul>
                </div>

                <div class="content-box type2">
                    <h3>Type 2 Pathogenesis</h3>
                    <div class="case-study">
                        <strong>Dual Defects Model:</strong><br>
                        1. Insulin resistance (primary)<br>
                        2. Œ≤-cell compensation (hyperinsulinemia)<br>
                        3. Progressive Œ≤-cell failure<br>
                        4. Overt hyperglycemia
                    </div>

                    <h4>Key Mechanisms</h4>
                    <ul>
                        <li><strong>Insulin resistance</strong>: Hepatic & peripheral</li>
                        <li><strong>Œ≤-cell dysfunction</strong>: Secretion defects</li>
                        <li><strong>Glucotoxicity</strong>: Chronic hyperglycemia</li>
                        <li><strong>Lipotoxicity</strong>: Excess fatty acids</li>
                    </ul>
                </div>
            </div>

            <div class="key-points">
                <strong>Type 1: </strong>Autoimmune destruction ‚Üí Œ≤-cell loss ‚Üí Absolute insulin deficiency<br>
                <strong>Type 2: </strong>Insulin resistance + Œ≤-cell failure ‚Üí Relative insulin deficiency
            </div>
        </div>

        <!-- Types of Diabetes -->
        <div class="slide" id="slide4">
            <h1 class="slide-title">Types of Diabetes Mellitus</h1>

            <div class="content-section">
                <div class="complications-grid">
                    <div class="complication type1">
                        <h3>Type 1 DM</h3>
                        <ul>
                            <li>Autoimmune Œ≤-cell destruction</li>
                            <li>Absolute insulin dependence</li>
                            <li>Peak incidence: 10-14 years</li>
                            <li>Global: 10-15% of cases</li>
                            <li>India: 5-10% of cases</li>
                        </ul>
                    </div>

                    <div class="complication type2">
                        <h3>Type 2 DM</h3>
                        <ul>
                            <li>Insulin resistance + Œ≤-cell failure</li>
                            <li>Gradual onset, often asymptomatic</li>
                            <li>Peak incidence: 45-65 years</li>
                            <li>Global: 85-90% of cases</li>
                            <li>India: 90-95% of cases</li>
                        </ul>
                    </div>

                    <div class="complication diagnosis">
                        <h3>Gestational DM</h3>
                        <ul>
                            <li>Glucose intolerance during pregnancy</li>
                            <li>Screen at 24-28 weeks</li>
                            <li>Maternal & fetal risks</li>
                            <li>Revert postpartum in most</li>
                            <li>High T2DM risk later</li>
                        </ul>
                    </div>

                    <div class="complication treatment">
                        <h3>Other Specific Types</h3>
                        <ul>
                            <li><strong>MODY</strong>: Genetic, young onset</li>
                            <li><strong>Mitochondrial</strong>: Maternal inheritance</li>
                            <li><strong>Pancreatic</strong>: Disease or resection</li>
                            <li><strong>Drug-induced</strong>: Steroids, diuretics</li>
                            <li><strong>Genetic syndromes</strong>: Down, Klinefelter</li>
                        </ul>
                    </div>
                </div>
            </div>

            <table class="criteria-table" style="margin-top: 40px;">
                <thead>
                    <tr>
                        <th>Feature</th>
                        <th>Type 1 DM</th>
                        <th>Type 2 DM</th>
                        <th>MODY</th>
                        <th>LADA</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Age at onset</strong></td>
                        <td><30 years</td>
                        <td>>40 years</td>
                        <td><25 years</td>
                        <td>>35 years</td>
                    </tr>
                    <tr>
                        <td><strong>Body habitus</strong></td>
                        <td>Normal</td>
                        <td>Often obese</td>
                        <td>Normal</td>
                        <td>Variable</td>
                    </tr>
                    <tr>
                        <td><strong>Antibodies</strong></td>
                        <td>+++</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+++</td>
                    </tr>
                    <tr>
                        <td><strong>C-peptide</strong></td>
                        <td>Low</td>
                        <td>Normal/high</td>
                        <td>Normal</td>
                        <td>Low</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <!-- Risk Factors -->
        <div class="slide" id="slide5">
            <h1 class="slide-title">Risk Factors & Etiology</h1>

            <div class="risk-factors">
                <div class="risk-factor">
                    <h4>Genetic Factors</h4>
                    <ul style="text-align: left; margin-top: 10px;">
                        <li>T1DM: HLA-DR3/DR4 (50-60%)</li>
                        <li>T2DM: TCF7L2, PPARG, KCNJ11</li>
                        <li>Family history: 3-4x increased risk</li>
                        <li>South Asian phenotype</li>
                    </ul>
                </div>

                <div class="risk-factor">
                    <h4>Lifestyle Factors</h4>
                    <ul style="text-align: left; margin-top: 10px;">
                        <li>Sedentary lifestyle: 1.4x risk</li>
                        <li>Unhealthy diet: High GI, processed foods</li>
                        <li>Smoking: 20-50% increased risk</li>
                        <li>Alcohol: Binge > moderate</li>
                    </ul>
                </div>

                <div class="risk-factor">
                    <h4>Metabolic Factors</h4>
                    <ul style="text-align: left; margin-top: 10px;">
                        <li>Obesity: BMI >25, central adiposity</li>
                        <li>Dyslipidemia: Low HDL, High TG</li>
                        <li>Hypertension: >130/80 mmHg</li>
                        <li>Metabolic syndrome</li>
                    </ul>
                </div>

                <div class="risk-factor">
                    <h4>Other Factors</h4>
                    <ul style="text-align: left; margin-top: 10px;">
                        <li>Age: Risk doubles per decade</li>
                        <li>GDM: 40-60% develop DM later</li>
                        <li>Polycystic ovary syndrome</li>
                        <li>Socioeconomic status</li>
                    </ul>
                </div>
            </div>

            <div class="content-section">
                <div class="content-box diagnosis">
                    <h3>Risk Assessment Tools</h3>
                    <h4>Indian Diabetes Risk Score (IDRS)</h4>
                    <ul>
                        <li>4 parameters: Age, abdominal obesity, family history, physical activity</li>
                        <li>Score range: 0-20</li>
                        <li>Risk categories: Low (<30), Medium (30-50), High (>50)</li>
                        <li>Sensitivity: 70-80%</li>
                    </ul>

                    <h4>FINDRISC Score</h4>
                    <ul>
                        <li>8 parameters including age, BMI, medications</li>
                        <li>Score ‚â•14: High risk (one-third will develop diabetes)</li>
                        <li>Validates across ethnic groups</li>
                    </ul>
                </div>

                <div class="content-box treatment">
                    <h3>Population Attributable Risk</h3>
                    <div class="key-points">
                        <strong>Major contributors to Indian diabetes epidemic:</strong><br>
                        ‚Ä¢ <span class="highlight">Obesity: 80-85% PAR</span><br>
                        ‚Ä¢ Physical inactivity: 7% PAR<br>
                        ‚Ä¢ Urbanization: 30% burden attributed<br>
                        ‚Ä¢ Dietary shifts: 15-20% contribution<br>
                        ‚Ä¢ Asian Indian phenotype: Higher risk at lower BMI
                    </div>

                    <h4>Emerging Risk Factors</h4>
                    <ul>
                        <li><strong>Sleep disorders</strong>: OSA, short sleep duration</li>
                        <li><strong>Vitamin D deficiency</strong>: High prevalence in South Asians</li>
                        <li><strong>Air pollution</strong>: PM2.5 associated with T2DM</li>
                        <li><strong>Endocrine disruptors</strong>: Bisphenol-A, phthalates</li>
                    </ul>
                </div>
            </div>
        </div>

        <!-- Clinical Features & Complications -->
        <div class="slide" id="slide6">
            <h1 class="slide-title">Clinical Features & Complications</h1>

            <div class="content-section">
                <div class="content-box type1">
                    <h3>Classic Symptoms (3 P's)</h3>
                    <ul class="clinical-features">
                        <li><strong>Polyuria</strong>: >3L urine/day, osmotic diuresis</li>
                        <li><strong>Polydipsia</strong>: Excessive thirst, dehydration</li>
                        <li><strong>Polyphagia</strong>: Hunger despite eating</li>
                        <li><strong>Fatigue</strong>: Reduced energy metabolism</li>
                        <li><strong>Weight loss</strong>: Especially in T1DM</li>
                        <li><strong>Blurred vision</strong>: Fluctuating hyperglycemia</li>
                    </ul>
                </div>

                <div class="content-box type2">
                    <h3>Physical Signs</h3>
                    <div class="complications-grid">
                        <div style="background: #ffeaa7; padding: 15px; border-radius: 8px; border-left: 4px solid #d63031;">
                            <h4>Skin Changes</h4>
                            <ul style="font-size: 0.9rem;">
                                <li>Acanthosis nigricans</li>
                                <li>Diabetic dermopathy</li>
                                <li>Fungal infections</li>
                            </ul>
                        </div>
                        <div style="background: #fd79a8; padding: 15px; border-radius: 8px; border-left: 4px solid #d63031;">
                            <h4>Oral Signs</h4>
                            <ul style="font-size: 0.9rem;">
                                <li>Periodontal disease</li>
                                <li>Candidiasis</li>
                                <li>Xerostomia</li>
                            </ul>
                        </div>
                        <div style="background: #6c5ce7; padding: 15px; border-radius: 8px; border-left: 4px solid #d63031; color: white;">
                            <h4>Foot Changes</h4>
                            <ul style="font-size: 0.9rem;">
                                <li>Neuropathy</li>
                                <li>Vascular insufficiency</li>
                                <li>Charcot's arthropathy</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

            <div class="treatment-algo">
                <h3>Complications: Microvascular vs Macrovascular</h3>
            </div>

            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 30px; margin-top: 30px;">
                <div class="complication">
                    <h4>üî¨ Microvascular Complications</h4>
                    <h5>Diabetic Retinopathy</h5>
                    <ul style="font-size: 0.9rem;">
                        <li>Non-proliferative (microaneurysms)</li>
                        <li>Proliferative (new vessels)</li>
                        <li>Maculopathy (vision loss)</li>
                    </ul>

                    <h5>Diabetic Nephropathy</h5>
                    <ul style="font-size: 0.9rem;">
                        <li>Hyperfiltration ‚Üí microalbuminuria</li>
                        <li>Macroalbuminuria ‚Üí CKD</li>
                        <li>Hypertension in early stages</li>
                    </ul>

                    <h5>Diabetic Neuropathy</h5>
                    <ul style="font-size: 0.9rem;">
                        <li>Distal symmetric polyneuropathy</li>
                        <li>Autonomic dysfunction</li>
                        <li>Painful vs painless neuropathy</li>
                    </ul>
                </div>

                <div class="complication">
                    <h4>‚ù§Ô∏è Macrovascular Complications</h4>
                    <h5>Coronary Artery Disease</h5>
                    <ul style="font-size: 0.9rem;">
                        <li>2-4x higher risk in diabetics</li>
                        <li>Atypical presentation</li>
                        <li>Diffuse vessel involvement</li>
                    </ul>

                    <h5>Cerebrovascular Disease</h5>
                    <ul style="font-size: 0.9rem;">
                        <li>2-6x higher stroke risk</li>
                        <li>Small vessel disease</li>
                        <li>Carotid artery thickening</li>
                    </ul>

                    <h5>Peripheral Arterial Disease</h5>
                    <ul style="font-size: 0.9rem;">
                        <li>Critical limb ischemia</li>
                        <li>Claudication</li>
                        <li>10-20x amputation risk</li>
                    </ul>
                </div>
            </div>
        </div>

        <!-- Management & Treatment -->
        <div class="slide" id="slide7">
            <h1 class="slide-title">Management & Treatment</h1>

            <div class="treatment-algo">
                <h3>ADA Treatment Algorithm (2024)</h3>
                <div style="display: flex; justify-content: center; align-items: center; gap: 20px; margin-top: 20px;">
                    <div class="treatment-step">Diagnosis</div>
                    <div class="treatment-step">Lifestyle + Metformin</div>
                    <div class="treatment-step">Dual Therapy</div>
                    <div class="treatment-step">Triple Therapy</div>
                    <div class="treatment-step">Insulin</div>
                </div>
            </div>

            <div class="content-section">
                <div class="content-box type1">
                    <h3>First-Line Therapy</h3>
                    <h4>Metformin</h4>
                    <ul>
                        <li><strong>Mechanism</strong>: ‚Üì Hepatic glucose production, ‚Üë peripheral uptake</li>
                        <li><strong>Dose</strong>: 500-1000 mg twice daily with meals</li>
                        <li><strong>Benefits</strong>: Weight neutral, CV protection, inexpensive</li>
                        <li><strong>Side effects</strong>: GI upset, B12 deficiency</li>
                        <li><strong>Contraindications</strong>: eGFR <30, liver disease</li>
                    </ul>
                </div>

                <div class="content-box type2">
                    <h3>Second-Line Additions</h3>
                    <h4>GLP-1 Receptor Agonists</h4>
                    <ul>
                        <li><strong>Examples</strong>: Dulaglutide (weekly), Semaglutide (oral/weekly)</li>
                        <li><strong>Benefits</strong>: Weight loss, CV protection, low hypoglycemia</li>
                        <li><strong>Use</strong>: High-risk patients, weight management</li>
                        <li><strong>Administration</strong>: Subcutaneous injection</li>
                    </ul>
                </div>
            </div>

            <div class="complications-grid" style="margin-top: 30px;">
                <div style="background: #a8e6cf; padding: 20px; border-radius: 10px;">
                    <h4>SGLT2 Inhibitors</h4>
                    <ul style="font-size: 0.9rem;">
                        <li>Empagliflozin, Dapagliflozin, Canagliflozin</li>
                        <li>Renal glucose excretion mechanism</li>
                        <li>CV & renal protection proven</li>
                        <li>Weight loss: 2-3 kg</li>
                        <li>Side effects: Genital infections, DKA</li>
                    </ul>
                </div>

                <div style="background: #ffd3a5; padding: 20px; border-radius: 10px;">
                    <h4>DPP-4 Inhibitors</h4>
                    <ul style="font-size: 0.9rem;">
                        <li>Sitagliptin, Vildagliptin, Teneligliptin</li>
                        <li>Glucose-dependent insulin secretion</li>
                        <li>Weight neutral, low hypoglycemia risk</li>
                        <li>Renal dose adjustment needed</li>
                        <li>No CV benefit proven</li>
                    </ul>
                </div>

                <div style="background: #ffaaa5; padding: 20px; border-radius: 10px;">
                    <h4>Sulfonylureas</h4>
                    <ul style="font-size: 0.9rem;">
                        <li>Glimepiride, Glipizide, Gliclazide</li>
                        <li>Insulin secretion stimulation</li>
                        <li>Rapid onset, inexpensive</li>
                        <li>Hypoglycemia risk, weight gain</li>
                        <li>Short-acting preferred (gliclazide)</li>
                    </ul>
                </div>

                <div style="background: #98d8c8; padding: 20px; border-radius: 10px;">
                    <h4>Insulin Therapy</h4>
                    <ul style="font-size: 0.9rem;">
                        <li>T1DM: Basal-bolus regimen</li>
                        <li>T2DM: Add to OHA failure</li>
                        <li>Basal: Degludec/Lantus (once daily)</li>
                        <li>Bolus: Aspart/Lispro pre-meal</li>
                        <li>Education essential before starting</li>
                    </ul>
                </div>
            </div>
        </div>

        <!-- Prevention -->
        <div class="slide" id="slide8">
            <h1 class="slide-title">Prevention Strategies</h1>

            <div class="prevention-strategies">
                <h3>Levels of Prevention</h3>
                <div style="display: grid; grid-template-columns: repeat(3, 1fr); gap: 20px; margin-top: 20px;">
                    <div style="text-align: center;">
                        <h4>Primary Prevention</h4>
                        <p>Prevent onset of diabetes in high-risk individuals</p>
                    </div>
                    <div style="text-align: center;">
                        <h4>Secondary Prevention</h4>
                        <p>Prevent progression of prediabetes to diabetes</p>
                    </div>
                    <div style="text-align: center;">
                        <h4>Tertiary Prevention</h4>
                        <p>Prevent complications and disability</p>
                    </div>
                </div>
            </div>

            <div class="content-section">
                <div class="content-box diagnosis">
                    <h3>Dietary Prevention</h3>
                    <h4>Key Principles</h4>
                    <ul>
                        <li><strong>Calorie control</strong>: 500 kcal deficit for weight loss</li>
                        <li><strong>Glycemic load</strong>: Low GI foods preferred</li>
                        <li><strong>Carbohydrates</strong>: 45-60% of calories</li>
                        <li><strong>Fiber intake</strong>: 25-30g/day</li>
                        <li><strong>Fat composition</strong>: <30% total, <10% saturated</li>
                    </ul>

                    <h4>Indian Context</h4>
                    <ul>
                        <li>Rice-based South ‚Üí Whole grains</li>
                        <li>Wheat-based North ‚Üí Whole wheat</li>
                        <li>Festival foods ‚Üí Healthy modifications</li>
                        <li>Cultural preferences ‚Üí Plant-based proteins</li>
                    </ul>
                </div>

                <div class="content-box treatment">
                    <h3>Lifestyle Interventions</h3>
                    <div class="key-points">
                        <strong>DPP Model Success:</strong><br>
                        ‚Ä¢ <span class="highlight">Weight loss: 5-7% of body weight</span><br>
                        ‚Ä¢ Physical activity: 150 minutes/week moderate<br>
                        ‚Ä¢ Dietary modification: Low calorie, low fat<br>
                        ‚Ä¢ Behavior change: Coaching sessions required<br>
                        ‚Ä¢ Maintenance: Support for 3+ years
                    </div>

                    <h4>Indian Adaptations</h4>
                    <ul>
                        <li><strong>Walking/cycling</strong>: Traditional transport</li>
                        <li><strong>Yoga</strong>: Cultural relevance</li>
                        <li><strong>Household activity</strong>: Integrated lifestyle</li>
                        <li><strong>Community programs</strong>: Group interventions</li>
                    </ul>
                </div>
            </div>

            <div class="case-study">
                <h4>DPP Results</h4>
                <p><strong>Lifestyle intervention</strong>: 58% reduction in diabetes incidence</p>
                <p><strong>Metformin</strong>: 31% reduction in diabetes incidence</p>
                <p><strong>Cost-effective</strong>: Initial intensive period followed by maintenance</p>
                <p><strong>Long-term benefit</strong>: Legacy effect persists years after intervention</p>
            </div>
        </div>

        <!-- Summary -->
        <div class="slide" id="slide9">
            <h1 class="slide-title">Summary & Key Takeaways</h1>

            <div class="learning-objectives">
                <h3>Diabetes Mellitus: Core Concepts</h3>
                <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin-top: 20px;">
                    <div>
                        <h4>Pathophysiology</h4>
                        <ul style="font-size: 0.9rem;">
                            <li>T1DM: Autoimmune Œ≤-cell destruction</li>
                            <li>T2DM: Insulin resistance + Œ≤-cell failure</li>
                            <li>Common pathways: Glucotoxicity, lipotoxicity</li>
                            <li>Genetic-environment interaction</li>
                        </ul>
                    </div>
                    <div>
                        <h4>Epidemiology</h4>
                        <ul style="font-size: 0.9rem;">
                            <li>Global: 537 million (2021)</li>
                            <li>India: 101.2 million (2nd highest)</li>
                            <li>Economic burden: $40-50 billion</li>
                            <li>Urban > Rural, South > North in India</li>
                        </ul>
                    </div>
                    <div>
                        <h4>Diagnosis</h4>
                        <ul style="font-size: 0.9rem;">
                            <li>FBS ‚â•126, 2hPG ‚â•200, HbA1c ‚â•6.5%</li>
                            <li>Symptomatic: Any single abnormality</li>
                            <li>Asymptomatic: Confirm with repeat testing</li>
                            <li>Screening: Age ‚â•45, high risk factors</li>
                        </ul>
                    </div>
                    <div>
                        <h4>Management</h4>
                        <ul style="font-size: 0.9rem;">
                            <li>Lifestyle foundation for all</li>
                            <li>Metformin first-line therapy</li>
                            <li>Individualized glycemic targets</li>
                            <li>Prevention better than cure</li>
                        </ul>
                    </div>
                </div>
            </div>

            <div class="key-points" style="margin-top: 30px;">
                <h4>Clinical Pearls for Practice</h4>
                <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 20px;">
                    <div>
                        <strong>Always suspect DM with 3 P's</strong><br>
                        Polyuria, Polydipsia, Polyphagia
                    </div>
                    <div>
                        <strong>Treat hypertension early</strong><br>
                        <130/80 mmHg target in diabetics
                    </div>
                    <div>
                        <strong>Foot examination essential</strong><br>
                        Annual comprehensive assessment
                    </div>
                    <div>
                        <strong>Educate before intensive therapy</strong><br>
                        Self-management crucial for success
                    </div>
                    <div>
                        <strong>Prevention focus</strong><br>
                        Lifestyle intervention proven effective
                    </div>
                    <div>
                        <strong>Mind comorbidities</strong><br>
                        CVD, CKD, mental health
                    </div>
                </div>
            </div>

            <div style="text-align: center; margin-top: 40px; font-style: italic; color: #7f8c8d;">
                <p>"Diabetes is not a disease to live with, it's a disease to prevent and manage actively"</p>
            </div>
        </div>
    </div>

    <div class="navigation">
        <button class="nav-btn" id="prevBtn" disabled>&larr; Previous</button>
        <span class="slide-counter" id="slideCounter">1 / 10</span>
        <button class="nav-btn" id="nextBtn">Next &rarr;</button>
    </div>

    <script>
        let currentSlide = 0;
        const slides = document.querySelectorAll('.slide');
        const prevBtn = document.getElementById('prevBtn');
        const nextBtn = document.getElementById('nextBtn');
        const slideCounter = document.getElementById('slideCounter');

        function showSlide(index) {
            slides.forEach(slide => slide.classList.remove('active'));
            slides[index].classList.add('active');

            slideCounter.textContent = `${index + 1} / ${slides.length}`;

            prevBtn.disabled = index === 0;
            nextBtn.disabled = index === slides.length - 1;
        }

        function nextSlide() {
            if (currentSlide < slides.length - 1) {
                currentSlide++;
                showSlide(currentSlide);
            }
        }

        function prevSlide() {
            if (currentSlide > 0) {
                currentSlide--;
                showSlide(currentSlide);
            }
        }

        prevBtn.addEventListener('click', prevSlide);
        nextBtn.addEventListener('click', nextSlide);

        // Keyboard navigation
        document.addEventListener('keydown', (e) => {
            if (e.key === 'ArrowLeft') {
                prevSlide();
            } else if (e.key === 'ArrowRight') {
                nextSlide();
            }
        });

        // Initialize
        showSlide(0);
    </script>
</body>
</html>
